CDKN2A and neoplasm: Even modest reduction in ATM function may be enough to impair its role in regulating p53 function sufficiently to permit enhanced genome instability in conjunction with the CDKN2A p14ARF variant, resulting in enhanced tumour progression and aggressiveness.